KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Leiser D, Medova M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F, Aebersold DM, Zimmer Y
Mol Oncol. 2015 Apr 14. pii: S1574-7891(15)00089-7. doi: 10.1016/j.molonc.2015.04.001. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.